Drug intelligence / Profile preview

2,4,6,8-(3)-Tetranitrophenyl-3,7-diazabicyclo[3.3.1]nonan-9-one

Development stage: Preclinical
Modality: Small Molecules

Overview

B16 is a synthesized bispidinone analog, chemically known as 2,4,6,8-(3)-Tetranitrophenyl-3,7-diazabicyclo[3.3.1]nonan-9-one. It has been shown to induce S-phase cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells. The mechanism of action involves increasing reactive oxygen species, decreasing mitochondrial membrane potential, activating the caspase cascade, and modulating Bcl-2 family proteins, leading to a caspase- and mitochondrial-dependent apoptotic pathway.

Beyond the preview

Go deeper on 2,4,6,8-(3)-Tetranitrophenyl-3,7-diazabicyclo[3.3.1]nonan-9-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,4,6,8-(3)-Tetranitrophenyl-3,7-diazabicyclo[3.3.1]nonan-9-one.

Explore the full profile